{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:48:37Z","timestamp":1762674517725,"version":"3.37.3"},"reference-count":13,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"4","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Clozapine is recognized as the drug of choice for treatment-refractory schizophrenia, but use may be limited because of strict monitoring requirements and adverse effects including severe neutropenia, seizures, and myocarditis. Loxapine is a first-generation antipsychotic with similarities to clozapine in both structure and receptor binding. This case describes a 57-year-old male with a history of severe paranoid schizophrenia despite treatment with clozapine and other psychotropic agents, who experienced clinical improvement after a cross titration from clozapine to loxapine. Loxapine may be a reasonable alternative in patients with treatment-refractory schizophrenia who do not tolerate or respond to clozapine.<\/jats:p>","DOI":"10.9740\/mhc.2021.07.263","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T17:41:56Z","timestamp":1626457316000},"page":"263-266","source":"Crossref","is-referenced-by-count":3,"title":["Loxapine in patient with clozapine-resistant psychosis"],"prefix":"10.9740","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5385-7521","authenticated-orcid":true,"given":"Jennifer","family":"Erley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3356-0106","authenticated-orcid":true,"given":"Sarah","family":"Goldsborough","sequence":"additional","affiliation":[{"name":"Psychiatry Pharmacy Resident, Michigan Medicine & University of Michigan College of Pharmacy, Ann Arbor, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2294-2694","authenticated-orcid":true,"given":"Amy","family":"VandenBerg","sequence":"additional","affiliation":[{"name":"Psychiatry Pharmacy Specialist, Michigan Medicine & University of Michigan College of Pharmacy, Ann Arbor, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-6766","authenticated-orcid":true,"given":"Alexandra","family":"Audu","sequence":"additional","affiliation":[{"name":"Psychiatry Resident, Michigan Medicine, Ann Arbor, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"2021071617405647900_i2168-9709-11-4-263-b01","doi-asserted-by":"crossref","unstructured":"Keepers\n              GA,\n            \n            \n              Fochtmann\n              LJ,\n            \n            \n              Anzia\n              JM,\n            \n            \n              Benjamin\n              S,\n            \n            \n              Lyness\n              JM,\n            \n            \n              Mojtabai\n              R,\n            \n            et al.\n          \n          The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia.\n\t\t\t\t\tAm J Psychiatry.\n\t\t\t\t\t2020;\n\t\t\t\t\t177(9):\n\t\t\t\t\t868-\n\t\t\t\t\t72.\n\t\t\t\t\tDOI: 10.1176\/appi.ajp.2020.177901. PubMed PMID: 32867516.","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"2021071617405647900_i2168-9709-11-4-263-b02","unstructured":"Mylan Pharmaceuticals Inc.\n\t\t\t\t\tClozapine tablet;\n\t\t\t\t\t1989[updated 2020 Jul; cited 2020 Sep].In:DailyMed [Internet].\n\t\t\t\t\tBethesda (MD):\n\t\t\t\t\tNational Library of Medicine (US).\n\t\t\t\t\tAvailable from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=883b5d43-0339-7dc1-f775-93791fb9b978"},{"key":"2021071617405647900_i2168-9709-11-4-263-b03","unstructured":"Mylan Pharmaceuticals Inc.\n\t\t\t\t\tLoxapine capsule;\n\t\t\t\t\t2004[updated 2017 Mar; cited 2020 Sep].In:DailyMed [Internet].\n\t\t\t\t\tBethesda (MD):\n\t\t\t\t\tNational Library of Medicine (US).\n\t\t\t\t\tAvailable from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=1a03c19b-d44f-ae98-f404-022eb8392677"},{"key":"2021071617405647900_i2168-9709-11-4-263-b04","doi-asserted-by":"crossref","unstructured":"Popovic\n              D,\n            \n            \n              Nuss\n              P,\n            \n            \n              Vieta\n              E.\n            \n          \n          Revisiting loxapine: a systematic review.\n\t\t\t\t\tAnn Gen Psychiatry.\n\t\t\t\t\t2015;\n\t\t\t\t\t14(1):\n\t\t\t\t\t15.\n\t\t\t\t\tDOI: 10.1186\/s12991-015-0053-3. PubMed PMID: 25859275; PubMed Central PMCID: PMC4391595.","DOI":"10.1186\/s12991-015-0053-3"},{"key":"2021071617405647900_i2168-9709-11-4-263-b05","doi-asserted-by":"crossref","unstructured":"Roth\n              BL,\n            \n            \n              Lopez\n              E,\n            \n            \n              Patel\n              S,\n            \n            \n              Kroeze\n              WK.\n            \n          \n          The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?\n          Neuroscientist.\n\t\t\t\t\t2000;\n\t\t\t\t\t6(4):\n\t\t\t\t\t252-\n\t\t\t\t\t62.\n\t\t\t\t\tDOI: 10.1177\/107385840000600408.","DOI":"10.1177\/107385840000600408"},{"key":"2021071617405647900_i2168-9709-11-4-263-b06","doi-asserted-by":"crossref","unstructured":"Kane\n              J.\n            \n          \n          Clozapine for the treatment-resistant schizophrenic.\n\t\t\t\t\tArch Gen Psychiatry.\n\t\t\t\t\t1988;\n\t\t\t\t\t45(9):\n\t\t\t\t\t789-\n\t\t\t\t\t96.\n\t\t\t\t\tDOI: 10.1001\/archpsyc.1988.01800330013001. PubMed PMID: 3046553.","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"2021071617405647900_i2168-9709-11-4-263-b07","doi-asserted-by":"crossref","unstructured":"Solmi\n              M,\n            \n            \n              Murru\n              A,\n            \n            \n              Pacchiarotti\n              I,\n            \n            \n              Undurraga\n              J,\n            \n            \n              Veronese\n              N,\n            \n            \n              Fornaro\n              M,\n            \n            et al.\n          \n          Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.\n\t\t\t\t\tTher Clin Risk Manag.\n\t\t\t\t\t2017;\n\t\t\t\t\t13:\n\t\t\t\t\t757-\n\t\t\t\t\t77.\n\t\t\t\t\tDOI: 10.2147\/TCRM.S117321. PubMed PMID: 28721057; PubMed Central PMCID: PMC5499790.","DOI":"10.2147\/TCRM.S117321"},{"key":"2021071617405647900_i2168-9709-11-4-263-b08","doi-asserted-by":"crossref","unstructured":"Schulte\n              PFJ.\n            \n          \n          What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.\n\t\t\t\t\tClin Pharmacokinet.\n\t\t\t\t\t2003;\n\t\t\t\t\t42(7):\n\t\t\t\t\t607-\n\t\t\t\t\t18.\n\t\t\t\t\tDOI: 10.2165\/00003088-200342070-00001. PubMed PMID: 12844323.","DOI":"10.2165\/00003088-200342070-00001"},{"key":"2021071617405647900_i2168-9709-11-4-263-b09","doi-asserted-by":"crossref","unstructured":"Plowchalk\n              DR,\n            \n            \n              Rowland Yeo\n              K.\n            \n          \n          Prediction of drug clearance in a smoking population: Modeling the impact of variable cigarette consumption on the induction of CYP1A2.\n\t\t\t\t\tEur J Clin Pharmacol.\n\t\t\t\t\t2012;\n\t\t\t\t\t68(6):\n\t\t\t\t\t951-\n\t\t\t\t\t60.\n\t\t\t\t\tDOI: 10.1007\/s00228-011-1189-y. PubMed PMID: 22258279.","DOI":"10.1007\/s00228-011-1189-y"},{"key":"2021071617405647900_i2168-9709-11-4-263-b10","unstructured":"Singh\n              AN,\n            \n            \n              Barlas\n              C,\n            \n            \n              Saeedi\n              H,\n            \n            \n              Mishra\n              R.\n            \n          \n          Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.\n\t\t\t\t\tJ Psychiatry Neurosci.\n\t\t\t\t\t2003;\n\t\t\t\t\t28(1):\n\t\t\t\t\t39-\n\t\t\t\t\t47.\n\t\t\t\t\tPubMed PMID: 12587849."},{"key":"2021071617405647900_i2168-9709-11-4-263-b11","doi-asserted-by":"crossref","unstructured":"Chakrabarti\n              A,\n            \n            \n              Bagnall\n              A,\n            \n            \n              Chue\n              P,\n            \n            \n              Fenton\n              M,\n            \n            \n              Palaniswamy\n              V,\n            \n            \n              Wong\n              W,\n            \n            et al.\n          \n          Loxapine for schizophrenia.\n\t\t\t\t\tCochrane Database Syst Rev.\n\t\t\t\t\t2007;\n\t\t\t\t\t4:CD001943.DOI: 10.1002\/14651858.CD001943.pub2. PubMed PMID: 17943763.","DOI":"10.1002\/14651858.CD001943.pub2"},{"key":"2021071617405647900_i2168-9709-11-4-263-b12","doi-asserted-by":"crossref","unstructured":"Mowerman\n              S,\n            \n            \n              Siris\n              S.\n            \n          \n          Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients.\n\t\t\t\t\tAnn Clin Psychiatry.\n\t\t\t\t\t1996;\n\t\t\t\t\t8(4):\n\t\t\t\t\t193-\n\t\t\t\t\t7.\n\t\t\t\t\tDOI: 10.3109\/10401239609147759. PubMed PMID: 8986313.","DOI":"10.3109\/10401239609147759"},{"key":"2021071617405647900_i2168-9709-11-4-263-b13","doi-asserted-by":"crossref","unstructured":"Aboueid\n              L,\n            \n            \n              McCarthy\n              RH.\n            \n          \n          Loxapine and cyproheptadine combined limit clozapine rebound psychosis and may also predict clozapine response.\n\t\t\t\t\tCase Rep Psychiatry.\n\t\t\t\t\t2016:\n\t\t\t\t\t6123913.\n\t\t\t\t\tDOI: 10.1155\/2016\/6123913. PubMed PMID: 27433365; PubMed Central PMCID: PMC4940529.","DOI":"10.1155\/2016\/6123913"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/11\/4\/263\/2868669\/i2168-9709-11-4-263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/11\/4\/263\/2868669\/i2168-9709-11-4-263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:24:05Z","timestamp":1731687845000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/11\/4\/article-p263.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,7,16]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2021.07.263","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}